Tokyo, Apr 5, 2006 (JCN) - Alfresa Pharma, a wholly owned subsidiary of Alfresa Holdings, has signed an agreement with Tanabe Seiyaku on modafinil, an agent for treating narcolepsy. Upon receiving approval, the two companies will co-promote the agent under the trade name of Modiodal in Japan. Further, they will proceed with research on the agent with the aim of expanding indications including obstructive sleep apnea syndrome and pediatric ADHD.
